Nifty
Sensex
:
:
15763.05
52586.84
-15.40 (-0.10%)
-66.23 (-0.13%)

Pharmaceuticals & Drugs - Global

Rating :
41/99

BSE: 532523 | NSE: BIOCON

386.35
30-Jul-2021
  • Open
  • High
  • Low
  • Previous Close
  •  383.45
  •  389.25
  •  381.10
  •  382.55
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  2792729
  •  10783.29
  •  487.75
  •  363.25

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 46,409.19
  • 68.70
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 48,752.39
  • N/A
  • 6.08

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 60.64%
  • 1.00%
  • 11.03%
  • FII
  • DII
  • Others
  • 15.91%
  • 7.48%
  • 3.94%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.79
  • 12.80
  • 8.82

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 9.55
  • 5.86
  • 2.99

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 9.15
  • 6.59
  • -3.22

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 31.00
  • 52.07
  • 55.66

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.72
  • 5.89
  • 6.25

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 20.83
  • 26.15
  • 26.43

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 21
Jun 20
Var%
Mar 21
Mar 20
Var%
Dec 20
Dec 19
Var%
Sep 20
Sep 19
Var%
Net Sales
1,760.60
1,693.80
3.94%
1,838.70
1,557.50
18.05%
1,851.00
1,716.80
7.82%
1,744.80
1,567.30
11.33%
Expenses
1,371.30
1,280.50
7.09%
1,402.90
1,238.90
13.24%
1,451.50
1,272.60
14.06%
1,353.40
1,164.50
16.22%
EBITDA
389.30
413.30
-5.81%
435.80
318.60
36.79%
399.50
444.20
-10.06%
391.40
402.80
-2.83%
EBIDTM
22.11%
24.40%
23.70%
20.46%
21.58%
25.87%
22.43%
25.70%
Other Income
47.20
18.30
157.92%
205.40
63.10
225.52%
27.90
35.80
-22.07%
15.50
38.40
-59.64%
Interest
19.90
12.50
59.20%
33.90
16.80
101.79%
4.80
17.70
-72.88%
6.50
13.80
-52.90%
Depreciation
194.80
166.80
16.79%
184.30
152.40
20.93%
186.30
144.00
29.38%
177.70
131.60
35.03%
PBT
221.80
252.30
-12.09%
435.60
212.50
104.99%
236.30
318.30
-25.76%
222.70
363.30
-38.70%
Tax
57.30
80.90
-29.17%
69.40
45.00
54.22%
48.90
84.80
-42.33%
22.30
100.10
-77.72%
PAT
164.50
171.40
-4.03%
366.20
167.50
118.63%
187.40
233.50
-19.74%
200.40
263.20
-23.86%
PATM
9.34%
10.12%
19.92%
10.75%
10.12%
13.60%
11.49%
16.79%
EPS
0.70
1.25
-44.00%
2.11
1.03
104.85%
1.41
1.69
-16.57%
1.41
1.80
-21.67%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Net Sales
7,195.10
7,105.80
6,300.50
5,514.40
4,123.40
3,891.10
3,347.40
3,089.80
2,877.30
2,485.30
2,332.10
Net Sales Growth
10.09%
12.78%
14.26%
33.73%
5.97%
16.24%
8.34%
7.39%
15.77%
6.57%
 
Cost Of Goods Sold
2,279.00
2,208.50
1,989.50
1,896.60
1,636.10
1,446.60
1,290.40
1,255.60
1,186.10
1,044.40
852.00
Gross Profit
4,916.10
4,897.30
4,311.00
3,617.80
2,487.30
2,444.50
2,057.00
1,834.20
1,691.20
1,440.90
1,480.10
GP Margin
68.33%
68.92%
68.42%
65.61%
60.32%
62.82%
61.45%
59.36%
58.78%
57.98%
63.47%
Total Expenditure
5,579.10
5,803.90
5,043.50
4,390.60
3,294.30
2,911.60
2,584.30
2,394.00
2,190.20
1,946.30
1,809.30
Power & Fuel Cost
-
270.30
246.10
239.80
189.00
156.40
184.70
176.70
162.40
142.60
97.20
% Of Sales
-
3.80%
3.91%
4.35%
4.58%
4.02%
5.52%
5.72%
5.64%
5.74%
4.17%
Employee Cost
-
1,741.00
1,458.80
1,165.30
931.10
747.00
610.10
533.40
466.30
389.40
307.60
% Of Sales
-
24.50%
23.15%
21.13%
22.58%
19.20%
18.23%
17.26%
16.21%
15.67%
13.19%
Manufacturing Exp.
-
1,019.20
864.60
721.20
335.70
391.50
203.70
81.20
62.90
95.20
113.20
% Of Sales
-
14.34%
13.72%
13.08%
8.14%
10.06%
6.09%
2.63%
2.19%
3.83%
4.85%
General & Admin Exp.
-
270.50
182.10
53.00
56.80
21.70
144.60
165.70
131.80
122.20
93.20
% Of Sales
-
3.81%
2.89%
0.96%
1.38%
0.56%
4.32%
5.36%
4.58%
4.92%
4.00%
Selling & Distn. Exp.
-
234.00
266.30
277.50
98.20
107.40
100.80
108.70
118.90
99.60
89.40
% Of Sales
-
3.29%
4.23%
5.03%
2.38%
2.76%
3.01%
3.52%
4.13%
4.01%
3.83%
Miscellaneous Exp.
-
60.40
36.10
37.20
47.40
41.00
50.00
72.70
61.80
52.90
89.40
% Of Sales
-
0.85%
0.57%
0.67%
1.15%
1.05%
1.49%
2.35%
2.15%
2.13%
11.01%
EBITDA
1,616.00
1,301.90
1,257.00
1,123.80
829.10
979.50
763.10
695.80
687.10
539.00
522.80
EBITDA Margin
22.46%
18.32%
19.95%
20.38%
20.11%
25.17%
22.80%
22.52%
23.88%
21.69%
22.42%
Other Income
296.00
605.20
507.50
414.30
206.20
157.10
83.90
53.10
55.90
56.70
63.80
Interest
65.10
57.70
64.90
70.90
61.50
26.00
29.30
8.90
1.70
8.10
12.40
Depreciation
743.10
715.10
552.20
447.80
385.10
277.20
248.70
221.00
203.60
179.30
175.80
PBT
1,116.40
1,134.30
1,147.40
1,019.40
588.70
833.40
569.00
519.00
537.70
408.30
398.40
Tax
197.90
221.50
315.10
212.30
156.90
161.60
142.20
95.70
106.90
97.50
55.90
Tax Rate
17.73%
19.31%
25.94%
17.49%
26.65%
19.39%
19.49%
15.33%
19.88%
15.98%
14.03%
PAT
918.50
819.70
777.10
904.40
351.10
595.80
528.70
497.40
413.80
508.90
341.60
PAT before Minority Interest
807.20
925.40
899.80
1,001.70
431.80
671.80
587.40
528.40
430.80
512.70
342.50
Minority Interest
-111.30
-105.70
-122.70
-97.30
-80.70
-76.00
-58.70
-31.00
-17.00
-3.80
-0.90
PAT Margin
12.77%
11.54%
12.33%
16.40%
8.51%
15.31%
15.79%
16.10%
14.38%
20.48%
14.65%
PAT Growth
9.92%
5.48%
-14.08%
157.59%
-41.07%
12.69%
6.29%
20.20%
-18.69%
48.98%
 
EPS
7.65
6.83
6.47
7.53
2.92
4.96
4.40
4.14
3.45
4.24
2.85

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Shareholder's Funds
7,626.90
6,705.80
6,098.00
5,180.80
4,837.70
4,033.80
3,270.60
3,026.70
2,694.60
2,272.40
Share Capital
600.00
600.00
300.00
300.00
100.00
100.00
100.00
100.00
100.00
100.00
Total Reserves
6,872.80
5,997.00
5,720.80
4,812.30
4,670.20
3,873.00
3,132.70
2,806.20
2,491.80
2,079.80
Non-Current Liabilities
5,496.90
2,684.70
2,122.30
2,006.50
2,304.60
2,421.30
1,377.90
1,262.00
666.30
645.20
Secured Loans
1,492.40
1,220.80
1,523.50
1,787.00
2,104.30
2,061.00
758.20
580.40
124.00
9.30
Unsecured Loans
1,469.20
1.40
2.10
2.80
3.90
11.40
11.40
25.80
40.00
60.50
Long Term Provisions
106.20
85.80
66.10
49.30
36.00
29.90
15.00
7.80
4.00
0.00
Current Liabilities
4,210.10
4,008.00
3,038.50
2,141.30
1,678.30
1,665.70
1,554.70
1,379.60
989.90
1,015.80
Trade Payables
1,513.90
1,325.10
1,198.30
1,005.30
739.70
609.80
429.30
347.20
345.50
347.80
Other Current Liabilities
1,840.20
1,784.40
1,374.70
870.10
698.20
527.10
706.20
612.30
313.10
269.20
Short Term Borrowings
594.20
667.60
261.20
130.30
97.20
394.90
261.00
243.50
84.80
187.30
Short Term Provisions
261.80
230.90
204.30
135.60
143.20
133.90
158.20
176.60
246.50
211.50
Total Liabilities
18,214.60
14,075.80
11,867.70
9,796.30
9,196.70
8,386.60
6,375.40
5,750.60
4,416.10
3,937.20
Net Block
6,363.90
5,971.10
4,471.00
3,699.50
3,625.10
1,748.30
1,629.90
1,525.20
1,510.30
1,270.50
Gross Block
10,220.90
9,147.40
7,095.00
5,873.80
5,436.10
3,403.60
3,034.20
2,701.70
2,480.90
2,066.20
Accumulated Depreciation
3,857.00
3,176.30
2,624.00
2,174.30
1,811.00
1,655.30
1,404.30
1,176.50
970.60
795.70
Non Current Assets
10,614.20
8,750.80
6,979.20
5,647.70
5,149.00
4,415.70
3,812.80
3,111.80
2,176.10
1,937.50
Capital Work in Progress
2,800.20
2,196.00
1,898.90
1,302.80
839.20
2,239.50
1,676.40
1,205.60
312.50
389.50
Non Current Investment
743.20
108.50
182.50
63.80
188.80
26.80
0.00
64.50
64.50
64.20
Long Term Loans & Adv.
436.40
402.00
335.80
437.20
319.70
350.10
336.90
252.00
241.60
181.00
Other Non Current Assets
270.50
73.20
91.00
144.40
176.20
51.00
169.60
64.50
47.20
32.30
Current Assets
7,600.40
5,325.00
4,888.50
4,148.60
4,047.70
3,970.90
2,562.60
2,638.80
2,240.00
1,999.70
Current Investments
1,208.70
857.60
829.30
611.40
1,065.00
874.70
230.30
700.40
522.10
492.10
Inventories
1,866.60
1,435.90
1,031.60
722.50
635.30
542.40
452.70
376.60
398.40
378.30
Sundry Debtors
1,217.60
1,223.70
1,291.80
1,063.90
883.20
714.50
770.50
599.80
509.70
491.70
Cash & Bank
2,015.40
998.60
1,057.20
1,322.80
1,044.30
1,538.60
937.50
804.40
672.90
523.30
Other Current Assets
1,292.10
543.60
525.50
373.30
419.90
300.70
171.60
157.60
136.90
114.30
Short Term Loans & Adv.
286.90
265.60
153.10
54.70
24.10
134.70
75.80
81.80
81.40
37.10
Net Current Assets
3,390.30
1,317.00
1,850.00
2,007.30
2,369.40
2,305.20
1,007.90
1,259.20
1,250.10
983.90
Total Assets
18,214.60
14,075.80
11,867.70
9,796.30
9,196.70
8,386.60
6,375.40
5,750.60
4,416.10
3,937.20

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Cash From Operating Activity
1,159.70
1,283.10
1,154.60
662.10
640.00
370.60
210.70
560.70
471.20
564.10
PBT
846.20
870.90
1,002.60
610.00
849.70
751.30
624.10
537.70
610.20
395.20
Adjustment
931.10
921.40
472.60
355.70
204.40
42.00
74.00
134.00
147.30
144.80
Changes in Working Capital
-423.80
-165.10
-29.10
-106.50
-211.10
-176.20
-354.00
37.70
-192.30
98.00
Cash after chg. in Working capital
1,353.50
1,627.20
1,446.10
859.20
843.00
617.10
344.10
709.40
565.20
638.00
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-193.80
-344.10
-291.50
-197.10
-203.00
-246.50
-133.40
-148.70
-94.00
-73.90
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-3,624.70
-1,558.90
-713.80
-684.00
-498.50
-1,141.70
-508.70
-938.10
-375.80
-359.50
Net Fixed Assets
-130.90
744.40
-280.60
-177.90
-215.90
-216.90
-57.90
-322.80
-213.80
-75.20
Net Investments
-456.90
-890.30
107.80
-310.70
-79.30
-3,688.10
328.50
125.80
38.00
-171.10
Others
-3,036.90
-1,413.00
-541.00
-195.40
-203.30
2,763.30
-779.30
-741.10
-200.00
-113.20
Cash from Financing Activity
2,564.00
387.60
-241.70
-239.70
-177.50
1,067.60
186.20
426.00
-8.60
-186.30
Net Cash Inflow / Outflow
99.00
111.80
199.10
-261.60
-36.00
296.50
-111.80
48.60
86.80
18.30
Opening Cash & Equivalents
824.70
659.30
449.00
710.20
757.50
457.50
557.00
474.00
369.00
359.00
Closing Cash & Equivalent
897.00
824.70
659.30
449.00
710.20
757.50
462.60
557.00
474.00
369.00

Financial Ratios

Consolidated /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Book Value (Rs.)
62.27
54.97
50.17
42.59
39.74
33.10
26.93
24.21
21.59
18.16
ROA
5.73%
6.94%
9.25%
4.55%
7.64%
7.96%
8.72%
8.47%
12.28%
9.10%
ROE
13.16%
14.26%
18.00%
8.74%
15.37%
16.31%
17.22%
15.68%
21.50%
16.59%
ROCE
11.30%
14.35%
16.11%
8.92%
12.59%
13.93%
15.30%
15.75%
22.47%
16.74%
Fixed Asset Turnover
0.73
0.78
0.85
0.73
0.89
1.05
1.09
1.12
1.11
1.18
Receivable days
62.70
72.86
77.96
86.05
74.35
80.16
80.09
69.48
72.22
75.67
Inventory Days
84.82
71.47
58.05
60.00
54.81
53.71
48.47
48.54
56.01
60.69
Payable days
84.76
81.60
81.98
87.98
78.68
71.28
58.15
55.73
65.24
70.25
Cash Conversion Cycle
62.76
62.74
54.04
58.07
50.48
62.59
70.42
62.29
62.99
66.11
Total Debt/Equity
0.58
0.40
0.40
0.44
0.48
0.62
0.35
0.30
0.10
0.12
Interest Cover
20.88
19.72
18.12
10.57
33.05
25.90
71.12
317.29
76.33
33.13

News Update:


  • Biocon reports 44% fall in Q1 consolidated net profit
    23rd Jul 2021, 14:07 PM

    Total consolidated income of the company increased by 5.59% at Rs 1807.80 crore for Q1FY22

    Read More
  • Sebi imposes fine of Rs 14 lakh on Biocon, its designated person for violation of market norms
    21st May 2021, 12:54 PM

    Designated person of the firm, Narendra Chirmule, who was employed with the company as senior vice president-R&D is facing a fine of Rs 5 lakh

    Read More
  • Biocon reports 92% rise in Q4 consolidated net profit
    29th Apr 2021, 11:32 AM

    Total income of the company increased by 26.13% at Rs 2044.10 crore for Q4FY21

    Read More
  • Biocon’s arm wins ISPE’s 2021 FOYA honorable mention award
    29th Apr 2021, 09:19 AM

    The company received an Honorable Mention award for its monoclonal antibodies drugs substances manufacturing facility

    Read More
  • Biocon’s arm receives European Commission approval for Biosimilar Bevacizumab
    26th Apr 2021, 09:44 AM

    The company has received approval following the positive recommendation by the CHMP of the European Medicines

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.